Ioltech Report issue

For profit Phase 2 Phase 3
Founded: La Rochelle France (1990)
Status: Acquired by Carl Zeiss Meditec, Inc. (2005)

Organization Overview

First Clinical Trial
2006
NCT00642135
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Ioltech (0) Acquired (3)

phenylephrine (Prefrin) (1 trial)

temozolomide (temodar) (1 trial)

tropicamide (mydriacyl) (1 trial)

Drugs in Phase 2 Trials (2)

Key: Ioltech (0) Acquired (2)

aminolevulinic acid (levulan) (1 trial)

fluorescein (2 trials)

Drugs in Other Trials (1)

Key: Ioltech (0) Acquired (1)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Premature Birth (Phase 3)

Overview

  • Highest Phase: None
  • # of Trials: 5
  • # of Trial APIs: 6